Additionally, multiple groups have found an increase in anti-tumor responses in CD39-deficient mice [203], CD73-deficient mice [204], and AR-deficient mice [205] experiments, making this axis become a potential therapeutic target in cancer immunotherapy. Here, ENTPD1 is linked to neoplasm.